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Eliminating or blocking 12/15-lipoxygenase
reduces neutrophil recruitment in mouse
models of acute lung injury
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Abstract
Introduction: Acute lung injury (ALI) is a common disease in critically ill patients with a high morbidity and
mortality. 12/15-lipoxygenase (12/15-LO) is an enzyme generating 12-hydroxy-eicosatetraenoic acid (12-HETE) and
15-HETE from arachidonic acid. It has been shown that 12/15-LO is involved in the regulation of vascular
permeability during ALI.
Methods: To test whether 12/15-LO participates in leukocyte recruitment into the lung, we investigated the role of
12/15-LO in mouse models of lipopolysaccharide (LPS)-induced pulmonary inflammation and acid-induced ALI, a
clinically relevant model of acute lung injury.
Results: The increase in neutrophil recruitment following LPS inhalation was reduced in 12/15-LO-deficient
(Alox15-/-) mice and in wild-type (WT) mice after the blocking of 12/15-LO with a pharmacological inhibitor. Bone
marrow chimeras revealed that 12/15-LO in hematopoietic cells regulates neutrophil accumulation in the interstitial
and alveolar compartments, whereas the accumulation of neutrophils in the intravascular compartment is
regulated by 12/15-LO in non-hematopoietic and hematopoietic cells. Mechanistically, the increased plasma levels
of the chemokine CXCL1 in Alox15-/- mice led to a reduced response of the neutrophil chemokine receptor CXCR2
to stimulation with CXCL1, which in turn abrogated neutrophil recruitment. Alox15-/- mice also showed decreased
edema formation, reduced neutrophil recruitment and improved gas exchange in an acid-induced ALI model.
Conclusions: Our findings suggest that 12/15-LO modulates neutrophil recruitment into the lung by regulating
chemokine/chemokine receptor homeostasis.
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Introduction
Acute lung injury (ALI) is a severe disease with a high
incidence [1]. ALI is associated with high mortality
despite improved treatment [1], causes 3.6 million hospi-
tal days per year, and thus is a huge burden for the health
care system [1]. ALI can occur as a consequence of extra-
pulmonary causes, including massive transfusion and
sepsis, and intrapulmonary causes, such as aspiration of
gastric content and pneumonia. During the development
of ALI, the alveolar-capillary integrity is compromised,
leading to neutrophil infiltration, interstitial and alveolar
edema formation, and diminished gas exchange [2]. As
yet, there are no specific treatments available for ALI.
Accumulation and recruitment of neutrophils to the lung
are key events in the development of ALI [2]. Neutrophil
recruitment to the lung occurs in a cascade-like process of
activation, intravascular accumulation, and transendothe-
lial and transepithelial migration [3]. Depending on the
underlying cause of ALI, different chemokines and adhe-
sion molecules participate in neutrophil recruitment [4].
It has been shown that CXCR2, the chemokine receptor
for CXCL1 (keratinocyte-derived chemokine, KC) and
CXCL2/3 (macrophage inflammatory protein 2, MIP-2) in
the mouse system, is involved in the regulation of vascular
permeability and in neutrophil recruitment in different
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models of ALI [5-7]. Following lipopolysaccharide (LPS)
inhalation, CXCR2 on non-hematopoietic and hematopoie-
tic cells each contributes about equally to neutrophil
recruitment into the lung [5]. Blocking of CXCR2 by a
pharmacological inhibitor or elimination of CXCR2 in
both cell types completely abolished neutrophil recruit-
ment into the alveolar space in response to inhaled LPS
[5,7]. A recently published study demonstrated that human
CXCL8 (interleukin 8; IL-8), a ligand for human CXCR1
and CXCR2 [8] can form complexes with autoantibodies
associated with the development and outcome of ALI in
patients [9].
Besides chemokines, lipid mediators are critically
involved in the development of pulmonary inflammation
and play important roles in the pathophysiology of aller-
gen-induced inflammation and lung remodeling in asthma
[10,11]. Lipoxygenases (LOX) are a family of enzymes cap-
able of incorporating oxygen into unsaturated fatty acids
[12]. Their nomenclature depends upon the position of
the carbon double bonds they oxidize counted from the
carboxyl terminus of the fatty acid [13]. 15-lipoxygenase is
expressed in humans and rabbits (15-LO) [14,15]. “Leuko-
cyte-type” 12-LO, which has some 15-LO activity, is
expressed in pigs, rats and mice [16]. A high homology
exists between 12/15-LO in mice and 15-LO in humans.
Thus, the murine 12/15-LO is most likely the mouse
ortholog of human 15-LO [17,18]. The most common
substrate for 12/15-LO, arachidonic acid, is released from
membrane phospholipids by phospholipase A2 in response
to inflammatory stimuli [19]. 12/15-LO metabolizes ara-
chidonic acid. This process yields short-lived, peroxidized
products, which are reduced or enzymatically converted to
12-hydroxyeicosatetraenoic acid (12-HETE) as well as
hepoxilins, lipoxins and others [20]. 12/15-LO is expressed
in a variety of tissues, with the highest expression levels in
monocytes and macrophages [21]. Lower expression levels
of 12/15-LO are found in endothelial cells [22] and other
tissues. 12-HETE has a variety of biological functions. It is
a potent, proinflammatory chemoattractant for neutrophils
[23]. 12-HETE exerts effects on endothelial cells as it influ-
ences cytoskeleton rearrangement [24] and cytokine
production [25]. 12-HETE may also induce adhesion
molecule expression on endothelial cells [26]. Further-
more, an implication of 12/15-LO in chronic inflammatory
processes has been reported [21]. In a previous study, the
development of allergic sensitization and airway inflamma-
tion has been demonstrated to be diminished in Alox15-/-
mice [11,27]. However, rabbits made transgenic for
human Alox15 were protected from atherosclerosis [28] or
LTB4- or IL-8-induced dermatitis [29], possibly through
protective metabolites. Besides 12/15-LO, the lipoxygenase
5-LO has been shown to be involved in inflammatory pro-
cesses, for example, the ventilator-induced lung injury
model [30]. We previously demonstrated that 12-HETE,
the product of 12/15-LO, produced by hematopoietic cells
plays a key role in the regulation of vascular permeability
in LPS-induced pulmonary inflammation and acid-
induced ALI through a CXCR2-dependent mechanism
[31].
The aim of this study was to investigate the role of
12/15-lipoxygenase on neutrophil recruitment into the
lung in murine models of LPS-induced pulmonary inflam-
mation and acid-induced acute lung injury. To reveal the
main source of 12/15-LO influencing neutrophil recruit-
ment, chimeric mice were generated by bone marrow
transplantation. To reveal the mechanisms by which
12/15-LO modulates neutrophil recruitment, we investi-




The animals used in this study were 8- to 12-week old
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME,
USA) and 12/15-LO deficient mice (Alox15-/-) backcrossed
to C57BL/6 for at least 10 generations [32]. The mice were
kept in a barrier facility under specific pathogen-free con-
ditions. All animal experiments were approved by the
Animal Care and Use Committees of the University of
Virginia (Charlottesville) and the University of Münster
(Germany).
Murine model of LPS-induced pulmonary inflammation
and acid-induced ALI
For the induction of pulmonary inflammation, mice were
placed in an enclosed chamber and exposed to nebulized
LPS from Salmonella enteritidis (500 µg/ml, Sigma-
Aldrich, St. Louis, MO, USA) for 30 minutes, as previously
described [7]. Control mice were exposed to aerosolized,
sterile saline for 30 minutes.
For some experiments, mice were injected with CDC
(Cinnamyl-3,4-Dihydroxy-a-Cyanocinnamate, Biomol
International, Philadelphia, PA, USA), a pharmacological
inhibitor of 12/15-LO. Mice received a single injection
(8 mg/kg, intraperitoneal (i.p.)) one hour before LPS
application.
Acid-induced ALI was performed as previously
described [33]. Briefly, after induction of general anesthe-
sia with ketamine (125 μg/g body weight; Sanofi-Aventis,
Paris, France), xylazine (12.5 μg/g body weight; Phoenix
Scientific, Inc., St. Joseph, MO, USA), and atropine sul-
fate (0.025 μg/g body weight; Fujisawa, Tokyo, Japan)
mice were placed on a heating pad and the ventral aspect
of the neck was incised to gain access to the trachea. A
total of 2 µl/g HCl (pH 1.5) was injected intratracheally,
followed by a bolus of air (30 µl/g). Tracheotomy was
performed and mice were mechanically ventilated with a
respirator (MiniVent Type 845, Hugo Sachs Elektronik,
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March-Hugstetten, Germany) for two hours (tidal
volume 10 µl/g; respiration rate 140/minute; fraction of
inspiratory oxygen (FiO2) 0.21). Control animals were
treated in the same way, except for the instillation of ster-
ile saline instead of HCl.
Neutrophil recruitment into the lung
Twenty-four hours after LPS-inhalation mice were eutha-
nized. Bronchoalveolar lavage (BAL) fluid was collected
(5 × 1 ml phosphate-buffered saline). The BAL was centri-
fuged and the neutrophils in the BAL fluid were counted
using Kimura staining.
Intravascular and interstitial neutrophils were distin-
guished by a flow cytometry-based method as described
previously [33]. Briefly, Alexa 633-labeled GR-1 antibody
(clone RB6-8C5, staining kit: Invitrogen Corp., Carlsbad,
CA, USA) to murine neutrophils was injected intrave-
nously five minutes prior to euthanasia. This procedure
labels only intravascular neutrophils as the time period is
not sufficient for the antibody to react with neutrophils
located in the interstitial or intraalveolar compartment.
Thoracotomy was performed, the inferior vena cava was
opened and non-adherent neutrophils were removed from
the pulmonary vasculature by perfusing the right ventricle
with 3 ml of saline with a constant pressure of 25 cmH2O.
After collection of the BAL, the lungs were removed,
minced and digested with an enzyme cocktail (collagenase
type XI, hyaluronidase type I-s, DNAse1, Sigma-Aldrich,
St. Louis, MO, USA) containing 65 µg unlabelled GR-1-
antibody at 37°C for 60 minutes. A cell suspension was
made by passing the digested lung tissue through a 70 µm
cell strainer (BD Falcon, Bedford, MA, USA). Red blood
cells were lysed and the remaining leukocytes were resus-
pended in PBS and counted. The fraction of neutrophils in
the suspension was determined by flow cytometry (Facs-
Calibur; BD Biosciences, San Jose, CA, USA). Neutrophils
were identified by their typical appearance in the forward/
sideward scatter (FSC/SSC) and their expression of CD45
(clone 30-F11), 7/4 (clone 7/4, both BD Pharmingen, San
Diego, CA, USA), and GR-1 (clone RB6-8C5, purified
from hybridoma supernatant). The labelled GR-1-antibody
was used to differentiate between intravascular (CD45+7/4
+GR-1+) and interstitial (CD45+7/4+GR-1-) neutrophils.
In vitro chemotaxis assay
The in vitro chemotaxis assay was performed as described
previously [5]. For the in vitro chemotaxis assay, isolated
neutrophils were labeled with calcein AM (5 μM; Molecu-
lar Probes, Eugene, OR, USA) [34]. A 96-well chemotaxis
system (ChemoTx, 3-µm filter pore size; Neuro Probe,
Inc., Gaithersburg, MD, USA) was loaded with triplicates
of recombinant CXCL1 (1-10,000 ng/ml; PeproTech,
Rocky Hill, NJ, USA) or fMLP (n-formyl-methionine-
leucine-phenylalanine, 1 to 10,000 ng/ml; Sigma-Aldrich,
Taufkirchen, Germany). Neutrophil suspension (2.5 × 105)
was placed on top of the filter above each well, and the
chamber was incubated for one hour at 37°C [5]. After
incubation, non-migrated cells and the filter were removed
and fluorescence in the wells was measured with a fluores-
cence plate reader.
Generation of 12/15-Lipoxygenase chimeric mice
To investigate the role of 12/15-Lipoxygenase from non-
and hematopoietic origin in pulmonary inflammation, we
generated chimeric mice as described previously [33].
Destruction of the native bone marrow in male recipient
mice was archived by fractional lethal irradiation in two
doses of 600 rad each (separated by four hours). WT
(C57BL/6) and 12/15-lipoxygenase-deficient mice served
as donors and/or recipients. The bone marrow isolation
from donor mice was performed under sterile conditions.
Approximately 5 × 106 cells were injected intravenously
into irradiated recipient mice. Experiments with chimeric
mice were performed six weeks after successful bone mar-
row transplantation.
Histology
To investigate changes in tissue morphology following
LPS-induced pulmonary inflammation, lungs were
removed, embedded in paraffin and cut in 5 µm thick
slices. Tissue samples were stained for CXCL1 (anti-mur-
ine KC, PeproTech, Rocky Hill, NJ, USA) using the avidin-
biotin technique (Vector Laboratories, Burlingame, CA,
USA) as described previously [35].
Surface staining and flow cytometry analysis
We analyzed the surface expression of CXCR2 on periph-
eral blood leukocytes by incubating whole blood samples
with CD45 (clone 30-F11), 7/4 (clone 7/4, both BD Bios-
ciences-Pharmingen, San Diego, CA, USA), GR-1 (clone
RB6-8C5), and CXCR2 (clone 242216, R&D Systems, Inc.,
Minneapolis, MN, USA). After red blood cell lysis with
1.5 M NH4Cl, flow cytometry was performed to quantita-
tively determine surface expression of CXCR2 (FacsCali-
bur, BD Biosciences, Franklin Lakes, NJ, USA).
CXCL1/2 measurement
CXCL1 and CXCL2 levels in the plasma with and with-
out LPS challenge were measured in triplicates using
ELISA kits according to the manufacturer’s protocol
(R&D Systems, Minneapolis, MN, USA). In order to
measure CXCL1 and CXCL2 in the lung tissue, lungs
were mechanically minced and incubated with extrac-
tion buffer containing 0.1% Triton X-100, 10 mM
EDTA, 100 mM e-aminocaproic acid, 0.01 mM Pepsta-
tin, 0.005 mM Leupeptin and 50 mM Tris at 4°C for
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18 hours. Samples were centrifuged and the CXCL1 and
CXCL2 concentration in the supernatant was quantified
using the ELISA kits as described above.
Statistics
Statistical analysis was performed with SPSS (version 9.0;
SPSS, Inc., Chicago, IL, USA). Statistical tests included
one-way analysis of variance, Student-Newman-Keuls test,
and t-test where appropriate. All data are presented as
mean ± SEM, P < 0.05 was considered significant.
Results
12/15-lipoxygenase is involved in LPS-induced pulmonary
inflammation
In order to investigate the role of 12/15-lipoxygenase in
pulmonary inflammation, mice were exposed to aeroso-
lized LPS for 30 minutes and neutrophil recruitment into
the different compartments of the lung was determined by
flow cytometry. In this model, neutrophil recruitment into
the lung peaks at 24 h after LPS inhalation [3]. After LPS
inhalation, the number of neutrophils transmigrated into
the interstitial compartment significantly increased in all
mice, but significantly less in Alox15-/- mice than in WT
mice (Figure 1A). LPS induced an increase of neutrophils
in the alveolar space in WT mice, which was reduced by
two-thirds in Alox15-/- mice (Figure 1B). Elimination of
12/15-LO in Alox15-/- mice decreased pulmonary edema
formation as measured by wet/dry ratio after LPS expo-
sure (Figure 1C) and decreased histological signs of lung
tissue damage (Figure 1D-G). Differential white blood cell
counts were not different between WT and Alox15-/-
mice. All mice survived the 24-hour observation period
following LPS administration.
Pharmacological inhibition of 12/15-LO reduces
neutrophil recruitment
In order to investigate if the acute blockade of 12/15-LO
with a pharmacological inhibitor also reduces neutrophil
recruitment, mice were treated with the 12/15-LO inhibi-
tor CDC one hour before LPS exposure. A single injection
of 8 mg/kg CDC significantly reduced the 12/15-LO activ-
ity, as measured by urinary 12-HETE concentration 24 h
later [36]. Pharmacological inhibition of 12/15-LO signifi-
cantly decreased neutrophil accumulation in the intravas-
cular (Figure 2A), interstitial (Figure 2B) and alveolar
compartments (Figure 2C), decreased pulmonary edema
formation (Figure 2D) and decreased the histological signs
of lung injury (Figure 2E-H) compared to control mice.
Hematopoietic and non-hematopoietic 12/15-LO is
responsible for different steps of neutrophil recruitment
into the lung
In order to distinguish between the role of hematopoie-
tic and non-hematopoietic 12/15-LO for neutrophil
recruitment, chimeric mice were generated by bone-
marrow transplantation. Elimination of either hemato-
poietic or non-hematopoietic 12/15-LO had no effect on
neutrophil accumulation in the intravascular compart-
ment (Figure 3A). Only mice lacking 12/15-LO in both
the hematopoietic and non-hematopoietic compartments
showed significantly reduced accumulation of neutrophils
in the intravascular compartment (Figure 3A), similar to
Alox15-/- mice (data not shown). The transmigration of
neutrophils into the interstitial and alveolar compartment
in response to LPS inhalation was reduced in mice lack-
ing 12/15-LO either in the hematopoietic or both com-
partments (Figure 3B, C).
Elimination of 12/15-LO activity alters chemokine
homeostasis
The chemokines CXCL1 and CXCL2 and their receptor
CXCR2 are critically involved in the development of pul-
monary inflammation and ALI [5,6,37,38]. Therefore, we
measured plasma CXCL1 and CXCL2 concentrations in
WT mice and Alox15-/- mice under baseline conditions
and 3 h after LPS inhalation. Alox15-/- mice showed sig-
nificantly higher CXCL1 and CXCL2 plasma concentra-
tions under baseline conditions compared to WT mice
(Figure 4A, B). After LPS exposure, CXCL1 and CXCL2
plasma concentrations were elevated in WT mice and
Alox15-/- mice and remained higher in Alox15-/- mice as
in WT mice. Similar to the chemokine concentrations in
the plasma, CXCL1 and CXCL2 concentrations in the
lung tissue were also higher under baseline conditions
and three hours after LPS exposure in Alox15-/- mice
compared to WT mice (Figure 4C, D). Comparable to
genetic ablation of Alox15, pharmacological blockade of
12/15-LO in WT mice caused increased CXCL1 plasma
levels (Figure 4E) and decreased CXCR2 expression on
circulating neutrophils (Figure 4F) compared to vehicle-
treated control mice under baseline conditions and after
LPS exposure. In order to investigate the location of the
CXCL1-producing cells, we conducted immunohisto-
chemistry of the lung for CXCL1. WT mice without LPS
inhalation showed almost no CXCL1-producing cells in
the lung (Figure 4G), whereas the number of CXCL1-pro-
ducing cells increased upon LPS exposure (Figure 4H).
Lungs from Alox15-/- mice showed some CXCL1-produ-
cing cells under baseline conditions (Figure 4I) and more
after LPS inhalation (Figure 4J).
Reduced response of neutrophils to CXCL1
In order to study the consequences of the altered chemo-
kine homeostasis in Alox15-/- mice, we investigated
CXCR2 expression on neutrophils. The elevated CXCL1
concentration in the plasma of Alox15-/- mice led to a
significant down-regulation of CXCR2 on the surface of
peripheral blood neutrophils from 33 ± 4 to 20 ± 3 mean
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Figure 1 12/15-lipoxygenase is involved in LPS-induced pulmonary inflammation. Neutrophil recruitment into the interstitial (A) and BAL
(B) compartments of the lung and the wet/dry ratio (C) of WT mice and Alox15-/- mice with (white bars) or without (black bars) LPS inhalation
(24 h) was measured by flow cytometry (n = 3 to 4). Exemplary histological images of lungs from WT mice and Alox15-/- mice under baseline
conditions and after LPS exposure (D-G). Bar indicates 50 µm. #P < 0.05, *P < 0.05 versus WT LPS.
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Figure 2 Pharmacological inhibition of 12/15-LO reduces neutrophil recruitment. (A-C) After pharmacological blockade of 12/15-LO by the
inhibitor CDC (Cinnamyl-3,4-Dihydroxy-a-Cyanocinnamate) or in vehicle control mice, neutrophil recruitment (24 h) into the lung was
investigated by flow cytometry. Number of neutrophils in the intravascular (A), interstitial (B), and alveolar compartments (C) (n = 4). Wet/dry
ratio under baseline conditions and after LPS exposure (D) (n = 3). Exemplary histological images of lungs from WT mice and Alox15-/- mice
under baseline conditions and after LPS exposure (E-H). Bar indicates 50 µm. #P < 0.05
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Figure 3 Hematopoietic 12/15-LO is responsible for the regulation of neutrophil recruitment into the lung. Neutrophil recruitment into
the lung in response to LPS (white bars) was tested in BM chimeras (WT into WT; WT into Alox15-/-; Alox15-/- into WT; Alox15-/- into Alox15-/-) (n =
4 to 5 mice per group). Mice lacking hematopoietic and non-hematopoietic Alox15 showed a reduced neutrophil accumulation in the
intravascular compartment 24 h after LPS inhalation (A). Reduced neutrophil recruitment into the interstitial (B) and alveolar (C) compartment
was observed when either hematopoietic or both hematopoietic and non-hematopoietic Alox15 was eliminated. n = 4 to 5. #P < 0.05.
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Figure 4 Elimination of 12/15-LO activity alters chemokine homeostasis. CXCL1 (A) and CXCL2 (B) concentrations in the plasma was
measured in WT mice (black bars) and Alox15-/- mice (white bars) under baseline conditions and 3 h after LPS inhalation (n = 3 to 4). CXCL1 (C)
and CXCL2 (D) concentrations in the lung were measured in WT mice (black bars) and Alox15-/- mice (white bars) under baseline conditions and
3 h after LPS inhalation (n = 3 to 4). CXCL1 concentration (E) was measured in the plasma of vehicle- or CDC-treated WT mice and CXCR2
expression (F) on circulating neutrophils under baseline conditions and 3 h after LPS inhalation was quantified by using flow cytometry (n = 3).
(G-J) CXCL1 protein expression shown by immunohistochemistry in WT and Alox15-/- mice under baseline conditions and 3 h after LPS
inhalation. Black arrows indicate CXCL1-producing cells (n = 3). Bar indicates 100 µm. #P < 0.05
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fluorescence intensity units (n = 3) as measured by flow
cytometry (Figure 5A). In order to show that the elevated
CXCL1 concentration observed in Alox15-/- mice indeed
causes the down-regulation of CXCR2 on the neutrophil
surface, we incubated isolated neutrophils from WT mice
with CXCL1 at a concentration of 10 pg/ml (as measured
in the BAL of Alox15-/- mice under baseline conditions)
at 37°C for one hour and could observe a significantly
reduced CXCR2 expression from 35 ± 3 to 18 ± 3 mean
fluorescence intensity units (n = 3) in untreated neutro-
phils (Figure 5B). To test the functional consequences of
CXCR2 down-regulation, an in vitro chemotaxis assay
was performed. Bone marrow-derived neutrophils from
both Alox15-/- and WT mice showed the same low
migration rate without a chemoattractant. Neutrophils
from WT mice migrated vigorously towards low concen-
trations of CXCL1 (10 ng/ml), whereas neutrophils from
Alox15-/- mice showed a very small response. High
CXCL1 concentrations (500 to 10,000 ng/ml) induced
similar migration rates in neutrophils from WT and
Alox15-/- mice. We calculated the chemotactic index
(migrated cells with chemoattractant/without chemoat-
tractant) and determined ED50 as 4.5 ng/ml in WT mice
and 40 ng/ml in Alox15-/- mice (Figure 5C). In order to
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Figure 5 Elimination of 12/15-LO leads to a reduced response of neutrophils to CXCL1. (A) Flow cytometry analysis of CXCR2 expression
was performed on peripheral blood neutrophils from WT and Alox15-/- mice under baseline conditions. Whole blood was stained for CD45, 7/4,
GR-1 and CXCR2. CXCR2 expression on the surface of peripheral blood neutrophils was determined by using flow cytometry. (n = 3). (B) Flow
cytometry analysis of CXCR2 expression on isolated neutrophils treated with or without CXCL1 (10 pg/ml) for one hour (n = 6). Migration of
labeled neutrophils from WT mice (circles) and Alox15-/- mice (triangles) toward different concentrations of CXCL1 (C) or fMLP (D) was
investigated in an in vitro chemotaxis assay. Neutrophils were applied on the top of the filter and allowed to migrate toward the
chemoattractant for one hour at 37°C. Migrated cells were measured by fluorescence intensity. Chemotactic index was calculated as the ratio of
migrated cells with chemoattractant to migrated cells without chemoattractant and ED50 was determined (n = 3).
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show that the lack or blockade of 12/15-LO specifically
abrogates CXCR2-dependent migration, we performed
additional chemotaxis assays with the chemoattractant
fMLP (n-formyl-methionine-leucine-phenylalanine).
There was no difference in the chemotactic index
between WT and Alox15-/- neutrophils (Figure 5D).
Taken together, the increased CXCL1 concentration in
the plasma of Alox15-/- mice led to reduced response of
neutrophils to CXCL1 through a reduced expression of
the chemokine-receptor CXCR2 on the cell surface. This
and perhaps other desensitization effects led to a reduced
neutrophil migration response to physiologically relevant
concentrations of CXCL1.
12/15-LO regulates neutrophil recruitment in acid-
induced acute lung injury
Based on our finding that the absence of 12/15-LO
reduces neutrophil recruitment in response to aerosolized
LPS, we hypothesized that this enzyme and its products
may also regulate neutrophil recruitment in a clinically
relevant model of acid-induced ALI [33]. Two hours after
induction of ALI, WT mice showed significantly elevated
neutrophil numbers in the BAL (Figure 6A), an increased
wet/dry ratio (Figure 6B) and compromised gas exchanges,
as measured by the paO2/FiO2 ratio (Figure 6C), which
was significantly attenuated in Alox15-/- mice. In addition,
the histological hallmarks of acute lung injury, that is,
invasion of immune cells, thickening of the interstitial
membrane and protein extravasation, were reduced in
Alox15-/- mice compared to WT animals, suggesting
that 12/15-LO regulates neutrophil recruitment and
affects edema formation in acid-induced lung injury
(Figure 6D-G). Similarly to genetic ablation of Alox15, the
pharmacological blockade of 12/15-LO decreased the
wet/dry ratio (Figure 7A), improved the gas exchange
(Figure 7B) and dampened the histological evidence of
acute lung injury in tissue samples (Figure 7C-F) in WT
mice treated with CDC compared to vehicle-treated con-
trol animals.
Discussion
Our findings suggest that 12/15-LO is critically involved in
the regulation of neutrophil recruitment into the different
compartments of the lung in LPS-induced pulmonary
inflammation and acid-induced ALI. Eliminating or block-
ing 12/15-LO reduced neutrophil recruitment into the
lung in different models of ALI. By using chimeric mice,
we demonstrated that hematopoietic and non-hemato-
poietic 12/15-LO is responsible for different steps of neu-
trophil recruitment into the lung. Elimination of 12/15-LO
reduces neutrophil recruitment into the lung by modulat-
ing chemokine/chemokine receptor homeostasis. .
Several studies established the role of 12/15-LO in dif-
ferent chronic inflammatory diseases, including arthritis
[39], atherosclerosis [21,40,41] and diabetes [42]. Two
products of 12/15-LO, 5-HETE and 12-HETE, have been
shown to be implicated in the regulation of vascular per-
meability during pulmonary inflammation following
Gram-negative endotoxemia [43]. A recently published
study demonstrated that 12/15-LO-derived 12-HETE
regulates vascular permeability in acute lung injury
through a CXCR2-dependent mechanism [31]. In pre-
vious studies, the elimination or pharmacological block-
ade of 12/15-LO positively influenced disease outcome,
and blocking 12/15-LO has been proposed as a possible
anti-inflammatory therapy [44,45]. However, the pro-
ducts of 12/15-LO are different in humans (mainly 15-
HETE) and mice (mainly 12-HETE). Here, we show that
12/15-LO regulates neutrophil recruitment into the lung
during ALI.
It has been shown that different factors, including differ-
ent adhesion molecules and chemoattractants, influence
neutrophil recruitment into the lung during ALI. It has
been demonstrated that the CXCL1-CXCR2 axis is the
main factor influencing neutrophil recruitment during ALI
[5,7]. Although other chemoattractant factors can influ-
ence neutrophil recruitment into the lung [46], a small
reduction of CXCR2 on the cell surface may have a sub-
stantial impact on neutrophil recruitment [6]. Our data
showing that the elimination or pharmacological blockade
of 12/15-LO modulates chemokine hemostasis and
neutrophil recruitment suggest that mainly the reduced
surface expression of CXCR2 is responsible for the dimin-
ished severity of ALI. However, we cannot exclude that
blocking or eliminating 12/15-LO influences other factors
that regulate neutrophil recruitment.
Macrophage-derived 12/15-LO plays an essential role
in the development of atherosclerosis in the apoE-/-
model [21]. Similar to this study, we show that 12/15-
LO expression in hematopoietic cells plays an important
role in acute lung injury as measured by interstitial and
alveolar neutrophil content. However, non-hematopoie-
tic 12/15-LO is also involved in neutrophil accumulation
in the vasculature of the lung. This finding is consistent
with the known expression of 12/15-LO in endothelial
cells, where the products of the enzyme induce the
expression of inflammatory adhesion molecules [26,47].
In the pulmonary vasculature, endothelial cells play an
active role in neutrophil recruitment. A recent study has
shown that endothelial Gai2 is critical for eosinophil
recruitment in ovalbumin-induced allergic airway
inflammation [48].
The inhibitory effect on neutrophil recruitment into the
different compartments of the lung was stronger in 12/15-
LO knockout mice than after pharmacological blockade of
12/15-LO. This effect can be explained by the pharmaco-
kinetics of the inhibitor CDC during the 24 hours between
LPS inhalation and mice sacrifice.
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Figure 6 12/15-LO-deficiency influences acid-induced acute lung injury. Acid-induced ALI was initiated by intratracheal instillation of 2 µl/g
HCL (pH 1.5) in WT and Alox15-/- mice. (A) After two hours, the lungs were lavaged and the neutrophil count in the BAL fluid was determined
(n ≥3 mice). (B) Wet/dry ratio of lungs from WT and Alox15-/- mice after saline (SAL) or HCL instillation (n = 3). (C) Arterial blood was withdrawn
from WT mice and Alox15-/- mice two hours after saline (SAL) or HCL instillation and the paO2/FiO2 ratio was calculated (n = 3). Exemplary
histological images of lungs from WT mice and Alox15-/- mice after saline (SAL) or HCL instillation (D-G). Bar indicates 50 µm. #P < 0.05
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The main pro-inflammatory product of 12/15-LO is
12-HETE [43]. Recently, the G protein-coupled receptor
GPR31 has been proposed as a receptor for 12-HETE
[49]. Knockdown of GPR31 inhibits 12-HETE-induced
cell invasion by PC-3M cells [49]. However, it is still
unknown whether the stimulation of GPR31 with 12-
HETE also regulates vascular permeability, neutrophil
recruitment and chemokine release. There is evidence
that the stimulation of neutrophils with 12-HETE acti-












































Figure 7 Pharmacological blockade of 12/15-LO influences acid-induced acute lung injury. Acid-induced ALI was initiated by intratracheal
instillation of 2 µl/g HCL (pH 1.5) in vehicle- and CDC-treated WT mice. (A) Wet/dry ratio of lungs from vehicle- and CDC-treated WT mice after
saline (SAL) or HCL instillation (n = 3). (B) Arterial blood was withdrawn from vehicle- and CDC-treated WT mice two hours after saline (SAL) or
HCL instillation and the paO2/FiO2 ratio was calculated (n = 3). Exemplary histological images of lungs from vehicle- and CDC-treated WT mice
after saline (SAL) or HCL instillation (C-F). Bar indicates 50 µm. #P < 0.05
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phosphoinositide 3-kinase, p21-activated kinase (PAK)
[50] and p38 mitogen-activated protein kinase [51]. Even
though the signaling cascade downstream of 12-HETE is
still unknown, the implication of PAK may be a hint for a
possible mechanism for the neutrophil effects of 12-
HETE. A recent study demonstrated that PAK in neutro-
phils influences migration into the lung following LPS
stimulation [52].
As 12/15-LO produces pro- and anti-inflammatory
mediators, the biology of this enzyme is very complex
[53]. 12/15-LO is involved in the biosynthesis of 12- and
15-HETE, 13 hydroxyoctadecadienoic acid and lipoxins
[54]. 15-HETE and lipoxins have been reported to exert
anti-inflammatory activities [55,56]. 15-HETE reduces
activation and recruitment of inflammatory cells and
modulates the expression of adhesion molecules [57,58].
12/15-LO is also involved in the production of the anti-
inflammatory eicosanoid lipoxin A4 (LXA4). Elimination
of 12/15-LO leads to a reduced expression of LXA4 [39].
LXA4 acts by reducing chemokine-sensitivity and conse-
cutively expression of adhesion molecules of effector cells
and thus limiting the inflammatory response [59]. These
results are well in accordance with our observations that
the elimination of 12/15-LO leads to increased CXCL1
levels under baseline and inflammatory conditions. This
altered chemokine homeostasis causes the reduced
expression of CXCR2 on neutrophils and leads to the
diminished neutrophil recruitment into the lung in ALI.
We observed a decreased in vitro chemotaxis of neutro-
phils from Alox15-/- mice towards lower concentrations
of CXCL1 while the chemotactic response was similar at
high CXCL1 concentrations. This goes along with the
observed CXCL1 concentrations in the lung tissue, which
were comparable to the medium range of the concentra-
tions used for the in vitro chemotaxis assay.
We confirmed the observations from the model of LPS-
induced pulmonary inflammation in a second model of
acid-induced lung injury. Although the total numbers of
neutrophils recruited to the alveolar compartment 2 hours
after acid instillation were lower than 24 hours after LPS
inhalation, the recruitment of neutrophils in this model
leads to the development of acute lung injury and a com-
promised gas exchange [33].
Conclusions
In recent years, the mortality of ALI has been reduced by
introducing new ventilation strategies [60], but there are
no drugs available to effectively and specifically reduce
neutrophil recruitment and vascular permeability to
improve survival. The present data suggest that 12/15-
LO produced by hematopoietic cells is an important
enzyme in regulating the accumulation of neutrophils in
the interstitial and alveolar compartments. Therefore,
blocking or eliminating 12/15-LO reduces neutrophil
recruitment and could lead to a survival benefit in acute
lung injury. We could show that inhibition of 12/15-LO
by CDC is effective as a pre-treatment. High doses of
CDC are required to inhibit 12/15-LO [61-63], thus a
more specific agent for the pharmacological blockade of
12/15-LO could be favorable as a possible new therapeu-
tic approach in the treatment of ALI.
Key messages
• 12/15-LO is required for neutrophil recruitment
into the lung during ALI
• 12/15-LO in hematopoietic cells is essential for
neutrophil recruitment into the interstitial and
alveolar compartment, whereas neutrophil recruit-
ment into the intravascular compartment is regu-
lated by 12/15-LO in hematopoietic and non-
hematopoietic cells
• Neutrophil recruitment is disturbed in 12/15-LO-
deficient mice, possibly by alterations in the CXCL1/
CXCR2 chemokine axis
• Absence of 12/15-LO reduces survival in an acid-
induced model of acute lung injury
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